REG - Immupharma PLC - Result of Broker Option / PDMR Dealings

ImmuPharmaAnnouncement

11/08/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220811:nRSK6371Va&default-theme=true

RNS Number : 6371V  Immupharma PLC  11 August 2022

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE
OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE
REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES
WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO
SELL OR A SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION, INCLUDING THE
UNITED STATES, CANADA, AUSTRALIA, JAPAN AND THE REPUBLIC OF SOUTH AFRICA.
NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS
OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER
IN ANY JURISDICTION.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
REGULATION 2014/596/EU. IN ADDITION, MARKET SOUNDINGS WERE TAKEN IN RESPECT OF
THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN
PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION. UPON THE PUBLICATION OF THIS
ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC
DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE
INFORMATION.

11 August 2022

ImmuPharma plc

 Result of Broker Option / PDMR Dealings

ImmuPharma plc ("ImmuPharma" or "the Company"), announces that it has raised
£0.95 million (before expenses) pursuant to a Broker Option following the
announcement made on 3 August 2022.

Under the terms of a placing agreement entered into by the Company with
Stanford Capital Partners Limited ("SCP") and SPARK Advisory Partners Limited
on 3 August, the Company granted an option to SCP to enable it to deal with
additional demand under the Placing in the event that requests to participate
in the Placing from qualifying investors were received during the period from
the time of the announcement of the Placing up to 5.00 p.m. on 10 August 2022,
up to a maximum of £1.3 million ("Broker Option"). SCP has exercised its
Broker Option in respect of 19 million Broker Option Shares at the same price
as the Placing.

Accordingly, the total number of Broker Option Shares to be issued by the
Company pursuant to the Broker Option is 19 million. The aggregate gross
proceeds of the Placing and the Broker Option is £1.04 million. Aggregate
proceeds, net of expenses, are expected to be approximately £0.97 million.

Certain directors of the Company have subscribed for shares in the Broker
Option as set out below:

 Name of Director  No of Broker Option Shares subscribed  Number of Ordinary Shares held post Admission  % of Ordinary Share Capital (as enlarged by the issue of the Lanstead
                                                                                                         Subscription Shares, the Placing Shares, the Broker Option Shares, the Value
                                                                                                         Payment Shares and the Fee Shares)
 Tim McCarthy      1,200,000                              1,488,462                                      0.46%
 Tim Franklin      400,000                                525,000                                        0.16%
 Lisa Baderoon     400,000                                583,963                                        0.18%

The Company will issue, conditional upon Admission, warrants to subscribe for
a total of 1 million  new Ordinary Shares at the Issue Price for a period of
10 years from Admission to Stanford Capital Partners (0.5 million) and SI
Capital (0.5 million).

Further to the announcement of 3 August 2022, the Directors confirm that the
fundraising, together with existing funding and funding arrangements, will
provide the Company with sufficient working capital for at least the next 12
months.

This is based on the assumptions detailed in the announcement of 3 August 2022
and the Directors undertaking active measures to limit or defer cash outflows
from the business in the near term, (which include the Directors deferring a
proportion of their salaries) until such time as the business is able to meet
these payments.

Settlement and dealings

Once issued, the rights of  Broker Option Shares will rank pari passu with
the Company's existing Ordinary Shares.

An application will be made for the Broker Option Shares to be admitted to
trading on AIM. Dealings in the Broker Option Shares on AIM are expected to
commence at 8:00 a.m. on or around 16 August 2022.

Total Voting Rights

Following Admission, the Company's issued share capital will comprise
325,803,104 Ordinary Shares with one voting right each and 284,984,933
deferred shares with no rights to vote. As the Company does not hold any
shares in treasury, the total number of voting rights in the Company is also
325,803,104 and this figure of Ordinary Shares may be used by shareholders as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
share capital of the Company under the FCA's Disclosure Guidance and
Transparency Rules.

Capitalised terms used in this announcement have the meanings given to them in
the announcement of the Lanstead Subscription and Placing on 3 August 2022.

 
**ENDS**

 

For further information, please contact:

 ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )        + 44 (0) 207 152 4080

 Tim McCarthy, Chief Executive Officer & Chairman

 Lisa Baderoon, Head of Investor Relations & Non-Executive Director      + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                                 +44 (0) 203 368 3550

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                                +44 20 3650 3650

 Patrick Claridge

 John Howes

 Bob Pountney

 SI Capital (Joint Broker)

 Nick Emerson                                                            +44 (0) 1483 413500

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Tim McCarthy
 2    Reason for the notification
 a)   Position/status                                              Chairman and Chief Executive Officer
 b)   Initial notification /Amendment                              Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         ImmuPharma PLC
 b)   LEI                                                          213800VZKGHXC7VUS895
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 1p each

      Identification code

                                                                   ISIN: GB0033711010
 b)   Nature of the transaction                                    Subscription for new Ordinary Shares
 c)   Price(s) and volume(s)                                       Price                        Volume

      5 pence                                                                                   1,200,000
 d)   Aggregated information                                       N/A

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      10 August 2022
 f)   Place of the transaction                                     Off market

 

 

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Ms Lisa Baderoon
 2    Reason for the notification
 a)   Position/status                                              Non - Executive Director
 b)   Initial notification /Amendment                              Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         ImmuPharma PLC
 b)   LEI                                                          213800VZKGHXC7VUS895
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 1p each

      Identification code

                                                                   ISIN: GB0033711010
 b)   Nature of the transaction                                    Subscription for new Ordinary Shares
 c)   Price(s) and volume(s)                                       Price                        Volume

      5 pence                                                                                   400,000

 d)   Aggregated information                                       N/A

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      10 August 2022
 f)   Place of the transaction                                     Off market

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Tim Franklin
 2    Reason for the notification
 a)   Position/status                                              Chief Operating Officer
 b)   Initial notification /Amendment                              Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         ImmuPharma PLC
 b)   LEI                                                          213800VZKGHXC7VUS895
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 1p each

      Identification code

                                                                   ISIN: GB0033711010
 b)   Nature of the transaction                                    Subscription for new Ordinary Shares
 c)   Price(s) and volume(s)                                       Price                        Volume

      5 pence                                                                                   400,000
 d)   Aggregated information                                       N/A

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      10 August 2022
 f)   Place of the transaction                                     Off market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFDEESEESEEA